J o u r n a l P r e -p r o o f Journal Pre-proof ABSTRACT Oxaliplatin therapy can be complicated by chemotherapy-induced peripheral neuropathy (CIPN). Other neurotoxic chemotherapies have been linked to single nucleotide variants (SNV) in Charcot-Marie-Tooth disease (CMT) genes. Whether oxaliplatin carries increased risks of CIPN due to SNV in CMT-associated genes is unknown.
INTRODUCTION
Clinical oncologists and pharmacists prescribing common cancer treatments have recently been alerted with increasing frequency to the possibility of encountering patients with a pre-existing genetic disorder termed Charcot-Marie-Tooth disease (CMT). CMT is a heterogeneous group of neuropathies with clinical features ranging from relatively mild, sensory-only neurological symptoms to severe neurological disability such as abasia. CMT ranks among the most common genetic diseases, with an incidence estimated at around 1/2500 individuals [1] . Most importantly, CMT may be under-diagnosed because this figure accounts only for symptomatic patients according to clinical criteria or abnormal by electrophysiological testing. The incidence of patients with occult CMT, such as those who carry a predisposition to developing CMT or a CMT-like neuropathy when exposed to neurotoxic agents, may be substantially higher.
severe neuropathy from chemotherapy that occurred in the setting of occult CMT . The authors concluded that rigorous screening of cancer patients for a personal CMT risk before prescribing any neurotoxic chemotherapy should be implemented widely in oncology.
The patients described by Ibañez-Juliá et al. [2] represent the extreme severity spectrum of chemotherapy induced peripheral neuropathy (CIPN). CIPN is a common side effect of vincristine (and other vinca alkaloids), paclitaxel and docetaxel (and other taxanes), bortezomib (and other novel oral agents), cisplatin, and oxaliplatin. CIPN usually worsens with each cycle of treatment, i.e., it is cumulative and can be dose-limiting. Mild CIPN such as occasional numbness and tingling in the extremities is so common that it may be expected to occur in most patients at least towards the end of a series of chemotherapy treatments. Knowing that a patient will eventually develop CIPN is therefore not a contraindication to the use of a particular neurotoxic drug. Most importantly, withholding chemotherapy on the basis of a risk of neurotoxocity may be problematic, especially if the withheld drug has a proven benefit in terms of survival or cure such as in several gastrointestinal cancers chemotherapy with oxaliplatin.
Genetic variants in CMT-associated genes may prompt concerns for CIPN risk, either if J o u r n a l P r e -p r o o f Journal Pre-proof these genes are analyzed in the scope of clinical pharmacogenomic testing or if encountered incidentally by clinicians. These concerns will most commonly be raised by single nucleotide variants (SNV) that are so infrequent among populations that no information is available whether they are benign or may represent a risk of occult CMT.
While such variants are individually rare, they are in aggregate common. If such SNV are encountered in CMT-associated genes , the concern may be heightened by recent studies that linked CIPN from taxanes to certain genetic variants in some of the CMT-associated genes including rare "singleton" SNV occurring in a given study population only once [3] [4] [5] .
As DNA sequencing technology has recently outpaced the availability of solid clinical evidence, clinicians are increasingly confronted with the question whether to incorporate a genetic test result of uncertain significance into a treatment recommendation and how to interpret many of the incidental findings. This situation also poses a risk of denying patients received prior treatment with neurotoxic chemotherapy such as oxaliplatin, cisplatin, a taxane, or a vinca alkaloid, were receiving any treatment for neuropathy at study entry, or had a family history of neuropathy. Written IRB-approved informed consent was obtained from all patients for the serial CIPN phenotype assessment and for collection of blood for genetic analysis (Mayo IRB# 10-001801). Data collection was performed by the Alliance Statistics and Data Center.
OIPN quantification by patient-reported outcomes
OIPN was quantified using the nine sensory items that are included in the EORTC QLQ-CIPN20, a dedicated patient-reported neuropathy instrument that has been well validated [7, 9] . Patients were asked to complete the CIPN20 instrument at the beginning of each oxaliplatin chemotherapy cycle, thereby providing a measure of symptoms as a function of cumulative oxaliplatin dose. The rate of symptom progression with increasing cumulative dose was used as an OIPN susceptibility score. It was computed using a studywide, Rasch-type statistical model [10] , which provided an estimate and standard error (SE) of the rate for each patient. The SE tended to be smaller when there were more CIPN20 measurements and when the cycle-to-cycle change was steady; conversely, the SE was larger J o u r n a l P r e -p r o o f if only few measurements were available or if the cycle-to-cycle change was unsteady (i.e., alternating up and down).
Selection of OIPN cases and controls
Using the estimate and SE for the rate of symptom progression, a confidence interval for the rate was formed for each patient. With patients ranked by the upper bound of the confidence interval, the lowest-ranking 25% of patients were selected as controls. Then, ranking patients by the lower bound of the confidence interval, the highest -ranking 25% of patients were selected as cases. Thus, patients whose symptoms worsened least with increasing cumulative dose were selected as controls, and patients who showed the most rapid worsening of symptoms were selected as cases. The purpose of using the upper and lower bounds, respectively, of the confidence interval was to account for uncertainty in the rate estimates. Focusing on 157 patients with the highest susceptibility to CIPN (cases) and the lowest susceptibility (controls), we sequenced and statistically analyzed all genetic variants in 49 canonical CMT-associated genes. Our patient selection method is described in detail in SI Methods 1.
J o u r n a l P r e -p r o o f
Journal Pre-proof 2.4 CMT-associated genes 49 CMT-associated genes were selected for this study, which are listed in SI Table 1 .
While the number of proven or candidate CMT may be even larger (approximately up to twice as many), we decided to focus on these genes for three reasons. First, they account for those accepted by most as canonical CMT-associated genes ; second, we studied the same set in a previous report on paclitaxel-induced CIPN [4] ; and, most importantly, we had defined this gene set at the outset of the present study as the primary endpoint for statistical analysis.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes, and sequencing libraries were prepared using SureSelect (Agilent) exome target enrichment. Sequencing was performed on a HiSeq 2000 system (Illumina) at the Genomics Core Facility sequencing laboratory at Mayo Clinic. BBDuk (https://sourceforge.net/projects/bbmap/), Picard (http://broadinstitute.github.io/picard/), BWA [11] , and Genome Analysis Toolkit (GATK) [12] were used to process sequencing reads and obtain SNV genotypes. Predicted SNV effects were obtained using Ensembl VEP [13] . Details of the data processing and variant filtering 
Orthogonal validation of genotyping
Sequencing results for a subset of SNV were validated for 471 genotype calls using SNV genotyping by mass spectrometry (Sequenom MassARRAY), an old, well-established genotyping method that we used as described previously [14, 15] .
Statistical analysis
The primary analysis was per-gene statistical testing for association between singleton SNV and CIPN susceptibility using a burden test in which the number of singletons found in a patient served as the explanatory variable in a univariate logistic regression of case vs. control status. The burden test p-value corresponds to the test of β=0, where β is the coefficient on the number of singletons. The co-primary analysis was testing for association between recurrent SNV and CIPN susceptibility using the Sequence Kernel Association Test variants" to which the title of this report refers. They are the object of the primary analysis of the study which supports the main conclusion. The remaining 127 SNV were identified in several patients in the study cohort, termed "recurrent" SNV. Of the synonymous SNV, 96
were singleton SNV and 182 were recurrent SNV in the study population.
Genotype validation
For a subset of 471 SNV calls (rs9038, rs17722209, rs6875902), the sequencing-based genotype was compared with the genotype obtained previously with a non-sequencing method on the same patients. Of these, validation data were missing in 4 instances for the SNV rs9038. 467 calls were informative by both methods. 467 of 467 of these instances agreed between the genotyping methods, providing orthogonal validation for the sequencing methodology employed.
DISCUSSION
CIPN is a serious adverse effect of several important chemotherapeutic drugs including oxaliplatin. The etiology and molecular mechanisms of CIPN are only incompletely understood and no preventive measures or effective treatment are currently available except not administering the offending drug. While CIPN is dose-dependent (in a cumulative fashion), its severity varies markedly amongst patients undergoing similar treatments indicating that individuals differ in terms of their susceptibility. CIPN has therefore been conceptualized and investigated as a candidate pharmacogenomic trait. The earliest pharmacogenomic studies of CIPN examined and found associations of SNV in drug metabolism genes [20, 21] . Over the current decade numerous other genes have been linked to CIPN through candidate SNV genotyping, genome-wide association studies (GWAS), and, most recently, the use of the high throughput sequencing technology employed in the current study. Commonalities across this literature could be viewed as follows. First, genetic associations appear to be different between drug classes, e.g., taxanes or vinca alkaloids or platinum drugs, and possibly also between individual drugs within a class such as cisplatin or oxaliplatin. Second, cross-validation between different studies has been only moderate (at J o u r n a l P r e -p r o o f Journal Pre-proof best) [22] ; lack of cross-validation may be due to patient phenotyping, study populations, shortcomings in statistical analyses such as retrospective identification of tests and endpoints (and therefore inflation of significance), or a combination of poor statistical power with expected stochastic variation. Third, any genetic effects are modest at best (typical hazard ratios and/or odds ratios are often close to 2); no single SNV is strongly predictive in a diagnostic sense. While genetic scores have been proposed (and used as retrospective endpoint) as a way out, no clinically convincing genetic test for CIPN exists today.
Alliance N08CB was a clinical trial conducted with the primary objective to investigate a prophylactic intervention to prevent OIPN. Unlike treatment studies concentrating on cancer response to oxaliplatin, this protocol was focused solely on the prospective assessment of OIPN, thereby creating one of the largest OIPN cohorts available to date with state-of-the-art clinical phenotypes. OIPN symptoms were assessed serially in all patientsup to 12 times during chemotherapy-allowing the present study to determine the OIPN susceptibility of individual patients from the rate of symptom change (usually worsening), which we describe as an OIPN susceptibility score in t he present report. This method for quantifying OIPN, which we have used in previous genetic association studies [3, 4] , has the J o u r n a l P r e -p r o o f Journal Pre-proof advantages of being intuitive and making full use of patients' reported symptom trajectories.
In the interest of transparency and reproducibility, we have provided a detai led description of our method as part of the supplementary material.
CMT-associated genes have been linked to CIPN from taxanes by multiple groups including ours [3, 5] . The rationale seems compelling because the symptomatology and neuropathology of CMT and CIPN certainly overlap markedly. Moderately strong ge netic evidence supporting the link has therefore not been surprising. At the same time, the genetic studies may have contributed to a renewed emphasis to screen for the possibility of occult CMT in cancer patients who are candidates for neurotoxic drugs [2] . This confluence of factors poses two (related) new questions for oncologists: First, should genetic testing be performed for CMT-associated genes in the knowledge that most patients will have genetic variants of uncertain significance in those genes (and only a small minority will have 
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